Recursion advances REC‑4881 to Phase 2

- Recursion Pharma said REC-4881, discovered using AI plus lab automation, has entered Phase 2 for familial atypical Parkinsonism, company posts said today. - Recursion reported the REC-4881 program reduced chemistry synthesis needs by about 90% during preclinical optimization, the company said July 9 update. - Company said REC-4881 moves to Phase 2 and shared preclinical data in its July 9 update. (x.com)